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73 SiRNA calnexin promotes endogenous F508del-CFTR trafﬁcking
D. Raveau1, A. Cantereau1, F. Becq1, C. Norez1. 1Institut de Physiologie et
Biologie Cellulaires, Universite´ de Poitiers, CNRS, Poitiers, France
The most common mutation in cystic ﬁbrosis (CF), F508del, results in CFTR (CF
transmembrane conductance regulator) protein that is retained in the endoplasmic
reticulum. Previously, we have shown that miglustat corrects the trafﬁcking of
F508del-CFTR and hypothesized that by inhibiting the interaction of F508del-
CFTR with calnexin, miglustat prevents its retention and degradation (Norez et al.,
2006). However, others contest the role of calnexin in the F508del-CFTR retention
(Chang et al., 2008). The purpose of this study was (i) to determine the effect
of Small interfering RNA (SiRNA) calnexin transfection on endogenous F508del-
CFTR trafﬁcking, (ii) to compare these results with a miglustat-induced correction,
(iii) to understand whether calnexin is implicated in the F508del-CFTR trafﬁcking.
SiRNA calnexin transfection was done on the CF-KM4 tracheal cell line to
inhibit expression of calnexin. The level of calnexin expression was veriﬁed by
biochemical technique and consequences on CFTR and ENaC activities were
assessed using single-cell ﬂuorescence imaging. We demonstrated that decreasing
calnexin expression restores F508del-CFTR activity at the plasma membrane. This
correction was associated with a decrease of ENaC activity. Surprisingly, we found
a higher level of correction induced by miglustat than the one of siRNA calnexin,
suggesting that inhibition of calnexin/F508del-CFTR interaction is probably not
sufﬁcient to fully explain the effects of miglustat raising the hypothesis that another
molecular target for this drug exists.
In conclusion, this work is in favor of a role of calnexin in the F508del-CFTR
retention and conﬁrms calnexin as a valuable CF therapeutic target.
Supported by Vaincre la Mucoviscidose and CNRS.
74* Agonists of peroxisome proliferator activated receptor gamma
(PPARg) modulate transepithelial anion secretion in human
bronchial epithelial cells
N. Madsen1, M. Duszyk1. 1Physiology, University of Alberta, Edmonton, AB,
Canada
The recognition that peroxisome proliferator activated receptors (PPARs) are
regulators of metabolic and inﬂammatory pathways has led to the development
and use of agonists of these receptors as therapeutic agents for wide variety of
diseases. Three different PPAR subtypes have been identiﬁed: PPARa, PPARb/d,
and PPARg. In this study we examined the role of PPARg agonists in human airway
transepithelial ion transport. We found that PPARg regulated both the cAMP and
Ca2+ signaling pathways. Forskolin and carbachol responses were examined to
determine ionic contributions to the decline in short circuit current (SCC) after
PPARg agonist treatment. The reduction in forskolin response was due to decreased
bicarbonate secretion, while the decrease in carbachol SCC was due to reduced
chloride secretion. ATP responses were modulated at both, apical and basolateral
membranes by PPARg agonists. While apical ATP SCC responses were increased,
basolateral ATP responses were decreased after PPARg agonist treatment. This
difference appears to be the result of increased apical calcium-dependent secretion
for the apical membrane response and decreased calcium dependent secretion for
the basolateral ATP response. The effect of PPARg on the expression of ion channels
and transporters was also examined. PPARg agonists regulated the expression of
NBC1 and CFTR. PPARg increased CFTR promoter activity in gene reporter assays
and increased CFTR mRNA detected by PCR. However, functional and western
blot data showed that CFTR expression was not increased. This suggests that while
CFTR is regulated by PPARg, homeostatic mechanisms prevent the overexpression
of CFTR in human bronchial epithelial cells.
Supported by: Studies supported by the Canadian Cystic Fibrosis Foundation.
75* Connexin 26 is implied in the regulation of airway epithelium
repair
S. Crespin1, M. Bacchetta1, I. Scerri1, T. Dudez1, M. Chanson1. 1Geneva
University Hospitals and Medical Faculty, Geneva, Switzerland
Functional integrity of the airway epithelium is altered in cystic ﬁbrosis (CF).
Epithelial integrity depends on the expression and assembly of speciﬁc proteins
into specialized junctional structures. Gap junctions, made of connexins (Cx)
hexamer, play crucial roles in these interactions by contributing to the ability of
cells to share signaling factors directly between adjacent cells. The pattern of Cx
expression in Human Airway Epithelial Cell (HAEC) cultures is associated with
the differentiation state. Thus, Cx26 is speciﬁcally expressed during proliferation
phase and its expression decreases to undetectable level with HAEC differentiation
to a polarized airway epithelium. In a model of HAEC repair, where the cultures
are mechanically wounded, Cx26 is transiently re-expressed at the wound area and
in basal cells behind the wound. The re-expression of Cx26 is associated with
enhanced spreading of the gap junction tracer Lucifer Yellow. In normal HAEC,
Cx26 detection is concomitant with the cell ability to proliferate, as evaluated by
Ki-67 detection, to close the gap following injury. The same phenomenon is seen
in HAEC from CF patients in higher proportion. Interestingly, the amount of Cx26,
the duration of its expression and the number of Ki-67-positive cells are ampliﬁed,
suggesting a hyperproliferative state of the CF airway epithelium. The use of gap
junction blockers delays the epithelial repair and targeting Cx26 with a speciﬁc
siRNA reduced HAEC proliferation. These results suggest that gap junctions, and
more speciﬁcally Cx26, play a role in airway epithelium wound repair and that
understanding of the underlying mechanisms may lead to identify new targets for
controlling CF HAEC proliferation and differentiation.
Supported by: “Vaincre la mucoviscidose” and FNRS.
76* Connexin channels mediate PGE2-dependent regulation of CFTR
activity in Calu-3 cells
D. Losa1, L. Scheckenbach1, T. Dudez1, M. Chanson1. 1Geneva University
Hospitals and Medical Faculty, Geneva, Switzerland
Connexins form hemichannels and gap junction channels enabling for extracel-
lular and intercellular coordination of tissue activity. In airway epithelial cells,
CFTR activity is regulated by protease-activated receptors (PAR) at the basolateral
membranes and adenosine (ADO) receptors at the apical membrane; both pathways
require the release of PGE2 to stimulate basolateral EP receptors and activate CFTR.
Interestingly, the extent of gap juctional intercellular communication (GJIC) was
modulated by ADO pathway in Calu-3 cells. ADO is produced by hydrolysis of
extracellular nucleotides by the membrane-bound ectoenzyme CD73. CD73 activity
in Calu-3 cells could be increased by stimulation with a methotrexate analogue or
inhibited by the CD73 blocker AMP-CP. Stimulation and inhibition of CD73 activity
enhanced and decreased GJIC, respectively, through ADO release. In addition,
inhibition of phospholipase A2 and cyclooxygenase prevented increase in GJIC
in response to the ADO receptor agonist NECA, suggesting for a role of PGE2
in this regulation. Indeed, PGE2 was also found to markedly increase GJIC in
Calu-3 cells. PAR-dependent activation of CFTR was dependent of GJIC. Thus,
reduction of GJIC with AMP-CP, a gap junction blocker and a speciﬁc connexin
mimetic peptide prevented CFTR currents induced by PAR in Ussing chambers.
CFTR currents were also inhibited with antagonists of EP2 and EP4 receptors,
again involving PGE2 in this mechanism. We further show that connexins form
hemichannels at the basolateral membrane. Work is in progress to test the hypothesis
that PGE2 release by hemichannels contribute to the regulation of CFTR activity
via cAMP intercellular propagation through gap junction channels.
Supported by: VLM, FNRS, Schmidheiny and Novartis Consumer Health.
